RA Capital Management, an American investment firm, led a $55m Series C round in Asher Bio, a biotechnology company, with participation from AstraZeneca and Bristol Myers Squibb, Janus Henderson Investors, Third Rock Ventures, Wellington Management and Boxer Capital. “Asher’s groundbreaking cis-targeting platform offers a highly differentiated approach to immunotherapy, with the potential to overcome the limitations of other immune-based treatments by maximizing efficacy and limiting off-target toxicities. The company has produced promising preclinical and early clinical data to date and we are excited to continue to support Asher as they further advance their lead program in the clinic,” Jake Simson, RA Capital Management Partner.